Kenichi Ogasawara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenichi Ogasawara has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Makoto Uchikawa
Department of Laboratory Japanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
13 shared publicationsHatsue Tsuneyama
Department of Laboratory Japanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
10 shared publicationsKazumi Isa
Japanese Red Cross Society Blood Service Headquarters, Central Blood Institute Tokyo Japan
10 shared publicationsM. Uchikawa
Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
8 shared publicationsH. Tsuneyama
Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
7 shared publicationsM. Satake
Japanese Red Cross Central Blood Institute, Tokyo, Japan
6 shared publications
Latest Publications
- 10 February 2025
- Published by Wiley in Transfusion
- Vol. 65 (3) , 604-614
Genetic background of anti‐CD99 producers in Japan and analysis of hemolytic transfusion reactions due to anti‐CD99
Background: The XG blood group system comprises two antigens, Xga and CD99. CD99 is known to be carried on both the X and Y chromosomes in pseudoautosomal region 1. We identified five unrelated Japanese individuals with anti‐CD99 and investigated their genomic background as well as the clinical significance of anti‐CD99.Study Design and Methods: Analysis of CD99 expression on RBCs and a modified monocyte monolayer assay was performed using flow cytometry. Genomic DNA was obtained from the five anti‐CD99 producers to identify the deleted region responsible for the lack of CD99, and we conducted a long polymerase chain reaction using primer pairs specific for CD99 and GYG2.Results: CD99 expression from the Y chromosome was higher than that from the X chromosome. The five anti‐CD99 plasma samples gave varied agglutination strengths with the red blood cells (RBCs) expressing high and low CD99 levels, in the antiglobulin test. The phagocytosis rate of anti‐CD99‐sensitized RBCs was 76.6% in one case indicating a risk of hemolytic transfusion reactions (HTR), and it correlated with the level of CD99 expression. The deleted region spanned 115 kb, from CD99 exon 3 to GYG2 exon 1. All five anti‐CD99 producers were homozygous for the large deletion allele.Discussion: All five anti‐CD99 producers were females with a history of pregnancy in Kyushu, Japan, and this deletion allele may thus be endemic. Our results indicated the possibility of HTR due to anti‐CD99, and the risk is low when transfusing RBC products from Xg(a‐) females with a low expression of CD99.
- 10 February 2025
- Published by Wiley in Transfusion
- Vol. 65 (3) , 604-614
Genetic background of anti‐CD99 producers in Japan and analysis of hemolytic transfusion reactions due to anti‐CD99
Background: The XG blood group system comprises two antigens, Xga and CD99. CD99 is known to be carried on both the X and Y chromosomes in pseudoautosomal region 1. We identified five unrelated Japanese individuals with anti‐CD99 and investigated their genomic background as well as the clinical significance of anti‐CD99.Study Design and Methods: Analysis of CD99 expression on RBCs and a modified monocyte monolayer assay was performed using flow cytometry. Genomic DNA was obtained from the five anti‐CD99 producers to identify the deleted region responsible for the lack of CD99, and we conducted a long polymerase chain reaction using primer pairs specific for CD99 and GYG2.Results: CD99 expression from the Y chromosome was higher than that from the X chromosome. The five anti‐CD99 plasma samples gave varied agglutination strengths with the red blood cells (RBCs) expressing high and low CD99 levels, in the antiglobulin test. The phagocytosis rate of anti‐CD99‐sensitized RBCs was 76.6% in one case indicating a risk of hemolytic transfusion reactions (HTR), and it correlated with the level of CD99 expression. The deleted region spanned 115 kb, from CD99 exon 3 to GYG2 exon 1. All five anti‐CD99 producers were homozygous for the large deletion allele.Discussion: All five anti‐CD99 producers were females with a history of pregnancy in Kyushu, Japan, and this deletion allele may thus be endemic. Our results indicated the possibility of HTR due to anti‐CD99, and the risk is low when transfusing RBC products from Xg(a‐) females with a low expression of CD99.
- Open Access
- 12 March 2024
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 51 (4) , 210-224
Review of ABO Expression and Variations based on Transcriptional Regulation of the ABO Blood Group Gene
Background and Summary: We review the transcriptional regulation of ABO expression and discuss variants in the promoter and erythroid cell-specific regulatory region in individuals with weak ABO phenotypes such as Bm, Am, B3, and A3. We also review the molecular mechanisms responsible for variations in ABO expression in development and disease including the cell type-specific expression of ABO during erythroid cell differentiation, and reduction of A- or B-antigens in cancer cells or on red blood cells in patients with leukemia. Although the relationship between ABO blood group antigens and diseases has been characterized, the physiological significance of the ABO blood group system remains unclear. Key Messages: This review discusses accumulated knowledge of the ABO gene regulation and potential reasons for conservation of ABO during evolution.
- 12 March 2024
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 51 (4) , 210-224
Open AccessReview of ABO Expression and Variations based on Transcriptional Regulation of the ABO Blood Group Gene
Background and Summary: We review the transcriptional regulation of ABO expression and discuss variants in the promoter and erythroid cell-specific regulatory region in individuals with weak ABO phenotypes such as Bm, Am, B3, and A3. We also review the molecular mechanisms responsible for variations in ABO expression in development and disease including the cell type-specific expression of ABO during erythroid cell differentiation, and reduction of A- or B-antigens in cancer cells or on red blood cells in patients with leukemia. Although the relationship between ABO blood group antigens and diseases has been characterized, the physiological significance of the ABO blood group system remains unclear. Key Messages: This review discusses accumulated knowledge of the ABO gene regulation and potential reasons for conservation of ABO during evolution.
- 11 May 2023
- Published by Wiley in Transfusion
- Vol. 63 (8) , 1441-1446
Two new JK silencing alleles identified by single molecule sequencing with 20‐Kb long‐reads
Background: The Kidd blood group gene SLC14A1 (JK) accounts for approximately 20 Kb from initiation codon to stop codon in the genome. In genomic DNA analysis using Sanger sequencing or short‐read‐based next generation sequencing, it is difficult to determine the cis or trans positions of single nucleotide variations (SNVs), which are occasionally more than 1 Kb away from each other. We aimed to determine the complete nucleotide sequence of a 20‐Kb genomic DNA amplicon to characterize the JK allelic variants associated with Kidd antigen silencing in a blood donor.Study Design and Methods: The Jk(a–b–) phenotype was identified in this donor by standard serological typing. A DNA sample obtained from whole blood was amplified by long‐range PCR to obtain a 20‐Kb fragment of the SLC14A1 gene, including the initiation and stop codons. The fragment was then analyzed by Sanger sequencing and single‐molecule sequencing. Transfection and expression studies were performed in CHO cells using the expression vector construct of JK alleles.Results: Sanger sequencing and single‐molecule sequencing revealed that the donor was heterozygous with JK*01 having c.276G>A (rs763262711, p.Trp92Ter) and JK*02 having c.499A>G (rs2298719, p.Met167Val), c.588A>G (rs2298718, p.Pro196Pro), and c.743C>A (p.Ala248Asp). The two JK alleles identified have not been previously described. Transfection and expression studies indicated that the CHO cells transfected with JK*02 having c.743C>A did not express the Jkb and Jk3 antigens.Conclusions: We identified new JK silencing alleles and their critical SNVs by single‐molecule sequencing and the findings were confirmed by transfection and expression studies.
- 11 May 2023
- Published by Wiley in Transfusion
- Vol. 63 (8) , 1441-1446
Two new JK silencing alleles identified by single molecule sequencing with 20‐Kb long‐reads
Background: The Kidd blood group gene SLC14A1 (JK) accounts for approximately 20 Kb from initiation codon to stop codon in the genome. In genomic DNA analysis using Sanger sequencing or short‐read‐based next generation sequencing, it is difficult to determine the cis or trans positions of single nucleotide variations (SNVs), which are occasionally more than 1 Kb away from each other. We aimed to determine the complete nucleotide sequence of a 20‐Kb genomic DNA amplicon to characterize the JK allelic variants associated with Kidd antigen silencing in a blood donor.Study Design and Methods: The Jk(a–b–) phenotype was identified in this donor by standard serological typing. A DNA sample obtained from whole blood was amplified by long‐range PCR to obtain a 20‐Kb fragment of the SLC14A1 gene, including the initiation and stop codons. The fragment was then analyzed by Sanger sequencing and single‐molecule sequencing. Transfection and expression studies were performed in CHO cells using the expression vector construct of JK alleles.Results: Sanger sequencing and single‐molecule sequencing revealed that the donor was heterozygous with JK*01 having c.276G>A (rs763262711, p.Trp92Ter) and JK*02 having c.499A>G (rs2298719, p.Met167Val), c.588A>G (rs2298718, p.Pro196Pro), and c.743C>A (p.Ala248Asp). The two JK alleles identified have not been previously described. Transfection and expression studies indicated that the CHO cells transfected with JK*02 having c.743C>A did not express the Jkb and Jk3 antigens.Conclusions: We identified new JK silencing alleles and their critical SNVs by single‐molecule sequencing and the findings were confirmed by transfection and expression studies.
- 12 March 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (5) , 392-397
DSLK and Kg: Antithetical antigens in the RHAG blood group system, and characterization of anti‐DSLK antibody
Background and Objectives: The RHAG blood group system contains five antigens: Duclos (RHAG001), Ola (RHAG002), DSLK (RHAG003), Kg (RHAG005) and SHER (RHAG006). Individuals who are DSLK‐negative and Kg‐positive have the same allele RHAG*01.–3, with a single‐nucleotide variation (rs144305805), c.490A>C (p.Lys164Gln), in exon 3 of the RHAG gene. We aimed to confirm whether DSLK and Kg are antithetical antigens.Materials and Methods: Blood samples of the original DSLK‐negative proband with anti‐DSLK, her son and another DSLK‐negative individual were examined. The RHAG gene was analysed by polymerase chain reaction and Sanger sequencing. Immunocomplex capture fluorescence assays (ICFAs) and monocyte phagocytosis assays were performed to characterize the anti‐DSLK antibody. Cross‐testing of alloanti‐DSLK and monoclonal anti‐Kg (OSK46) was performed using transduced HEK293 cells by inducing the construct of expression vectors encoding wild‐type RHAG*01 or the variant RHAG*01.–3.Results: ICFA using monoclonal anti‐RHAG (LA18.18) revealed that the anti‐DSLK and anti‐Kg antibodies reacted with the wild‐type and variant RhAG (Rh‐associated glycoprotein), respectively. The proband and a DSLK‐negative individual appeared to be homozygous for variant RHAG*01.–3, and the proband's son was typed as RHAG*01/RHAG*01.–3 heterozygote. HEK293 cells with wild‐type RhAG reacted with the anti‐DSLK but not anti‐Kg antibody, whereas HEK293 cells expressing the variant RhAG reacted with the anti‐Kg but not anti‐DSLK antibody. Monocyte phagocytosis assays indicated that 64% of red cells sensitized with anti‐DSLK were phagocytosed by monocytes.Conclusion: Our results demonstrate that DSLK and Kg are antithetical antigens in the RHAG blood group system. Anti‐DSLK may be a clinically significant antibody.
- 12 March 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (5) , 392-397
DSLK and Kg: Antithetical antigens in the RHAG blood group system, and characterization of anti‐DSLK antibody
Background and Objectives: The RHAG blood group system contains five antigens: Duclos (RHAG001), Ola (RHAG002), DSLK (RHAG003), Kg (RHAG005) and SHER (RHAG006). Individuals who are DSLK‐negative and Kg‐positive have the same allele RHAG*01.–3, with a single‐nucleotide variation (rs144305805), c.490A>C (p.Lys164Gln), in exon 3 of the RHAG gene. We aimed to confirm whether DSLK and Kg are antithetical antigens.Materials and Methods: Blood samples of the original DSLK‐negative proband with anti‐DSLK, her son and another DSLK‐negative individual were examined. The RHAG gene was analysed by polymerase chain reaction and Sanger sequencing. Immunocomplex capture fluorescence assays (ICFAs) and monocyte phagocytosis assays were performed to characterize the anti‐DSLK antibody. Cross‐testing of alloanti‐DSLK and monoclonal anti‐Kg (OSK46) was performed using transduced HEK293 cells by inducing the construct of expression vectors encoding wild‐type RHAG*01 or the variant RHAG*01.–3.Results: ICFA using monoclonal anti‐RHAG (LA18.18) revealed that the anti‐DSLK and anti‐Kg antibodies reacted with the wild‐type and variant RhAG (Rh‐associated glycoprotein), respectively. The proband and a DSLK‐negative individual appeared to be homozygous for variant RHAG*01.–3, and the proband's son was typed as RHAG*01/RHAG*01.–3 heterozygote. HEK293 cells with wild‐type RhAG reacted with the anti‐DSLK but not anti‐Kg antibody, whereas HEK293 cells expressing the variant RhAG reacted with the anti‐Kg but not anti‐DSLK antibody. Monocyte phagocytosis assays indicated that 64% of red cells sensitized with anti‐DSLK were phagocytosed by monocytes.Conclusion: Our results demonstrate that DSLK and Kg are antithetical antigens in the RHAG blood group system. Anti‐DSLK may be a clinically significant antibody.
- 14 September 2022
- Published by Wiley in Vox Sanguinis
- Vol. 117 (10) , 1235-1239
Genetic background of anti‐Xga producers in Japanese blood donors
Background and Objectives: The Xg blood group is composed of two antigens, Xga (XG1) and CD99 (XG2 and MIC2). The XG and CD99 are homologous genes located on pseudoautosomal region 1 of the X and Y chromosomes. The expressions of Xga and CD99 are co‐regulated by a single nucleotide polymorphism (rs311103) in the GATA‐1 binding region. Another mechanism of the Xg(a−) phenotype is the genomic deletion of approximately 114 kb, including the XG gene. Anti‐Xga seems to be naturally occurring by detection in males who have never been transfused.Materials and Methods: In this study, we identified 23 anti‐Xga producers among 580,115 donors (0.004%). Additional 12 anti‐Xga producers were also identified from a separate cohort.Results: All 35 anti‐Xga producers were male. Genomic DNA was obtained from 34 of 35 producers, and all 34 producers were confirmed to carry the XG‐gene‐deficient allele (XGdel). The breakpoints of all 34 producers were identical. The XGdel was also identified in 12 non‐producers of anti‐Xga among 860 donors who have no antibodies against RBCs, and the breakpoints were also identical with the anti‐Xga producers.Conclusion: Our results will serve as the basis for a more complete understanding of Xg blood group polymorphisms.
- 14 September 2022
- Published by Wiley in Vox Sanguinis
- Vol. 117 (10) , 1235-1239
Genetic background of anti‐Xga producers in Japanese blood donors
Background and Objectives: The Xg blood group is composed of two antigens, Xga (XG1) and CD99 (XG2 and MIC2). The XG and CD99 are homologous genes located on pseudoautosomal region 1 of the X and Y chromosomes. The expressions of Xga and CD99 are co‐regulated by a single nucleotide polymorphism (rs311103) in the GATA‐1 binding region. Another mechanism of the Xg(a−) phenotype is the genomic deletion of approximately 114 kb, including the XG gene. Anti‐Xga seems to be naturally occurring by detection in males who have never been transfused.Materials and Methods: In this study, we identified 23 anti‐Xga producers among 580,115 donors (0.004%). Additional 12 anti‐Xga producers were also identified from a separate cohort.Results: All 35 anti‐Xga producers were male. Genomic DNA was obtained from 34 of 35 producers, and all 34 producers were confirmed to carry the XG‐gene‐deficient allele (XGdel). The breakpoints of all 34 producers were identical. The XGdel was also identified in 12 non‐producers of anti‐Xga among 860 donors who have no antibodies against RBCs, and the breakpoints were also identical with the anti‐Xga producers.Conclusion: Our results will serve as the basis for a more complete understanding of Xg blood group polymorphisms.
- 9 August 2021
- Published by Wiley in Transfusion
- Vol. 61 (10) , 2825-2829
GP.MOT: A novel glycophorin variant identified in a Japanese blood donor
Background: In this study, we identified a novel glycophorin variant (GP.MOT) in a Mia‐positive Japanese blood donor. The proband with this glycophorin variant was discovered by antigen screening of samples from 475,493 Japanese blood donors using monoclonal anti‐Mia.Study design and methods: Standard serological techniques and flow cytometry were performed. GP.MOT RBCs were examined by immunoblotting using anti‐GPA, anti‐MUT or anti‐Mur. Genome DNA was extracted from whole blood, and the GYPA/GYPB was analyzed by polymerase chain reactions and Sanger sequencing.Results: The MNS blood group of the proband was M + N + wS‐s + with the presence of other low‐frequency antigens including Mia, Mur, MUT, and KIPP. A 43‐kDa molecule, which is almost equivalent in size to glycophorin A (GPA), was identified by immunoblotting using monoclonal anti‐MUT and anti‐Mur. Sanger sequencing clearly indicated that the proband had two different GYPA*M alleles at SNP rs62334651 (GYPA*M232 + 55A and GYPA*M232 + 55G), as well as a GYP(B‐A) hybrid allele (GYP*MOT) with breakpoints located on pseudoexon 3 of GYPB from c.210 to c.219.Discussion: We identified a hybrid glycophorin GP.MOT with the deduced unique amino acid sequence GPB (20–45)‐GPΨB (46–70)‐GPA (71–149), which has not been previously reported.
- 9 August 2021
- Published by Wiley in Transfusion
- Vol. 61 (10) , 2825-2829
GP.MOT: A novel glycophorin variant identified in a Japanese blood donor
Background: In this study, we identified a novel glycophorin variant (GP.MOT) in a Mia‐positive Japanese blood donor. The proband with this glycophorin variant was discovered by antigen screening of samples from 475,493 Japanese blood donors using monoclonal anti‐Mia.Study design and methods: Standard serological techniques and flow cytometry were performed. GP.MOT RBCs were examined by immunoblotting using anti‐GPA, anti‐MUT or anti‐Mur. Genome DNA was extracted from whole blood, and the GYPA/GYPB was analyzed by polymerase chain reactions and Sanger sequencing.Results: The MNS blood group of the proband was M + N + wS‐s + with the presence of other low‐frequency antigens including Mia, Mur, MUT, and KIPP. A 43‐kDa molecule, which is almost equivalent in size to glycophorin A (GPA), was identified by immunoblotting using monoclonal anti‐MUT and anti‐Mur. Sanger sequencing clearly indicated that the proband had two different GYPA*M alleles at SNP rs62334651 (GYPA*M232 + 55A and GYPA*M232 + 55G), as well as a GYP(B‐A) hybrid allele (GYP*MOT) with breakpoints located on pseudoexon 3 of GYPB from c.210 to c.219.Discussion: We identified a hybrid glycophorin GP.MOT with the deduced unique amino acid sequence GPB (20–45)‐GPΨB (46–70)‐GPA (71–149), which has not been previously reported.
- 6 July 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (1) , 94-98
Frequencies of glycophorin variants and alloantibodies against Hil and MINY antigens in Japanese
Background and Objectives: Antigens of the MNS blood group system are expressed on the red blood cell (RBC) membrane on glycophorin A (GPA) and glycophorin B (GPB) or on hybrid molecules of GPA and GPB. This study investigated the distribution of glycophorin variants and alloantibodies against Hil and MINY among Japanese individuals.Methods: Mi(a+) or Hil+ RBCs were screened using an automated blood grouping machine (PK7300) with monoclonal anti‐Mia or polyclonal anti‐Hil. Glycophorin variants were defined by serology with monoclonal antibodies against Mia, Vw, MUT and Mur, and polyclonal antibodies against Hil, MINY and Hop + Nob (KIPP). The glycophorin variants were further confirmed by immunoblotting and Sanger sequencing. Alloanti‐Hil and alloanti‐MINY in the plasma were screened using GP.Hil RBCs in an antiglobulin test. The specificity of anti‐Hil or anti‐MINY was assessed using GP.Hil (Hil+MINY+) and GP.JL (Hil‒MINY+) RBCs.Results: The GP.HF, GP.Mur, GP.Hut, GP.Vw, GP.Kip and GP.Bun frequencies in 1 005 594 individuals were 0·0357%, 0·0256%, 0·0181%, 0·0017%, 0·0009% and 0·0007%, respectively. GP.Hil was found in as four of the 13 546 individuals (0·0295%). Of 137 370 donors, 10 had anti‐Hil (0·0073%) and three had anti‐MINY (0·0022%).Conclusions: Glycophorin variants were relatively rare in Japanese individuals, with the major variants being GP.HF (0·0357%), GP.Hil (0·0295%) and GP.Mur (0·0256%). Only one example of anti‐MINY was previously reported, but we found three more in this study.
- 6 July 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (1) , 94-98
Frequencies of glycophorin variants and alloantibodies against Hil and MINY antigens in Japanese
Background and Objectives: Antigens of the MNS blood group system are expressed on the red blood cell (RBC) membrane on glycophorin A (GPA) and glycophorin B (GPB) or on hybrid molecules of GPA and GPB. This study investigated the distribution of glycophorin variants and alloantibodies against Hil and MINY among Japanese individuals.Methods: Mi(a+) or Hil+ RBCs were screened using an automated blood grouping machine (PK7300) with monoclonal anti‐Mia or polyclonal anti‐Hil. Glycophorin variants were defined by serology with monoclonal antibodies against Mia, Vw, MUT and Mur, and polyclonal antibodies against Hil, MINY and Hop + Nob (KIPP). The glycophorin variants were further confirmed by immunoblotting and Sanger sequencing. Alloanti‐Hil and alloanti‐MINY in the plasma were screened using GP.Hil RBCs in an antiglobulin test. The specificity of anti‐Hil or anti‐MINY was assessed using GP.Hil (Hil+MINY+) and GP.JL (Hil‒MINY+) RBCs.Results: The GP.HF, GP.Mur, GP.Hut, GP.Vw, GP.Kip and GP.Bun frequencies in 1 005 594 individuals were 0·0357%, 0·0256%, 0·0181%, 0·0017%, 0·0009% and 0·0007%, respectively. GP.Hil was found in as four of the 13 546 individuals (0·0295%). Of 137 370 donors, 10 had anti‐Hil (0·0073%) and three had anti‐MINY (0·0022%).Conclusions: Glycophorin variants were relatively rare in Japanese individuals, with the major variants being GP.HF (0·0357%), GP.Hil (0·0295%) and GP.Mur (0·0256%). Only one example of anti‐MINY was previously reported, but we found three more in this study.
- 1 June 2020
- Published by Wiley in Transfusion
- Vol. 60 (6) , 1287-1293
A new antigen SUMI carried on glycophorin A encoded by the GYPA*M with c.91A>C (p.Thr31Pro) belongs to the MNS blood group system
BACKGROUND MNS is one of the highly polymorphic blood groups comprising many antigens generated by genomic recombination among the GYPA, GYPB, and GYPE genes as well as by single-nucleotide changes. We report a patient with red blood cell (RBC) antibody against an unknown low-frequency antigen, tentatively named SUMI, and investigated its carrier molecule and causal gene. STUDY DESIGN AND METHODS Standard serologic tests, including enzyme tests, were performed. Monoclonal anti-SUMI-producing cells (HIRO-305) were established by transformation and hybridization methods using lymphocytes from a donor having anti-SUMI. SUMI+ RBCs were examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens. Genomic DNA was extracted from whole blood, and the GYPA gene was analyzed by polymerase chain reactions and Sanger sequencing. RESULTS Serologic screening revealed that 23 of the 541,522 individuals (0.0042%) were SUMI+, whereas 1351 of the 10,392 individuals (13.0%) had alloanti-SUMI. SUMI antigen was sensitive to ficin, trypsin, pronase, and neuraminidase, but resistant to alpha-chymotrypsin and sulfydryl-reducing agents. ICFA revealed that the SUMI antigen was carried on glycophorin A (GPA). According to Sanger sequencing and cloning, the SUMI+ individuals had a GYPA*M allele with c.91A>C (p.Thr31Pro), which may abolish the O-glycan attachment site. CONCLUSIONS The new low-frequency antigen SUMI is carried on GPA encoded by the GYPA*M allele with c.91A>C (p.Thr31Pro). Neuraminidase sensitivity suggests that glycophorin around Pro31 are involved in the SUMI determinant.
- 1 June 2020
- Published by Wiley in Transfusion
- Vol. 60 (6) , 1287-1293
A new antigen SUMI carried on glycophorin A encoded by the GYPA*M with c.91A>C (p.Thr31Pro) belongs to the MNS blood group system
BACKGROUND MNS is one of the highly polymorphic blood groups comprising many antigens generated by genomic recombination among the GYPA, GYPB, and GYPE genes as well as by single-nucleotide changes. We report a patient with red blood cell (RBC) antibody against an unknown low-frequency antigen, tentatively named SUMI, and investigated its carrier molecule and causal gene. STUDY DESIGN AND METHODS Standard serologic tests, including enzyme tests, were performed. Monoclonal anti-SUMI-producing cells (HIRO-305) were established by transformation and hybridization methods using lymphocytes from a donor having anti-SUMI. SUMI+ RBCs were examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens. Genomic DNA was extracted from whole blood, and the GYPA gene was analyzed by polymerase chain reactions and Sanger sequencing. RESULTS Serologic screening revealed that 23 of the 541,522 individuals (0.0042%) were SUMI+, whereas 1351 of the 10,392 individuals (13.0%) had alloanti-SUMI. SUMI antigen was sensitive to ficin, trypsin, pronase, and neuraminidase, but resistant to alpha-chymotrypsin and sulfydryl-reducing agents. ICFA revealed that the SUMI antigen was carried on glycophorin A (GPA). According to Sanger sequencing and cloning, the SUMI+ individuals had a GYPA*M allele with c.91A>C (p.Thr31Pro), which may abolish the O-glycan attachment site. CONCLUSIONS The new low-frequency antigen SUMI is carried on GPA encoded by the GYPA*M allele with c.91A>C (p.Thr31Pro). Neuraminidase sensitivity suggests that glycophorin around Pro31 are involved in the SUMI determinant.
- 11 May 2020
- Published by Wiley in Vox Sanguinis
- Vol. 115 (8) , 756-766
Novel hybrid genes and a splice site mutation encoding the Sta antigen among Japanese blood donors
Background The low‐incidence antigen Sta of the MNS system is usually associated with the GP(B‐A) hybrid molecule, which carries the ‘N’ antigen at the N terminus. The GP(A‐A) molecule with trypsin‐resistant M antigen has been found in a few St(a+) individuals. Materials and Methods Among Japanese blood donors, we screened 24 292 individuals for the presence of St(a+) with trypsin‐resistant ‘N’ antigen and 193 009 individuals for the presence of St(a+) with trypsin‐resistant M antigen. The breakpoints responsible for the Sta antigen were analysed by sequencing the genomic DNAs. Results A total of 1001 (4·1%) individuals were identified as St(a+) with trypsin‐resistant ‘N’ antigen. Out of 1001 individuals, 115 were selected randomly for sequencing. Two novel GYP*Sch (GYP*401) variants with new intron 3 breakpoints of GYPA were detected in three cases. Twenty‐five (0·013%) individuals were identified as St(a+) with trypsin‐resistant M antigen. Five individuals had the GYP(A‐ψB‐A) hybrid allele; two of these five individuals were GYP*Zan (GYP*101.01), and the remaining three had a novel GYP(A‐ψB‐A) allele with the first breakpoint in GYPA exon A3 between c.178 and c.203. Nine individuals had a novel GYP(A‐E‐A) allele with GYPE exon E2 and pseudoexon E3 instead of GYPA exon A2 and A3. The 11 remaining individuals had a novel GYP(A‐A) allele with a 9‐bp deletion that included the donor splice site of intron 3 of GYPA. Conclusion Our finding on diversity of glycophorin genes responsible for Sta antigen provides evidence for further complexity in the MNS system.
- 11 May 2020
- Published by Wiley in Vox Sanguinis
- Vol. 115 (8) , 756-766
Novel hybrid genes and a splice site mutation encoding the Sta antigen among Japanese blood donors
Background The low‐incidence antigen Sta of the MNS system is usually associated with the GP(B‐A) hybrid molecule, which carries the ‘N’ antigen at the N terminus. The GP(A‐A) molecule with trypsin‐resistant M antigen has been found in a few St(a+) individuals. Materials and Methods Among Japanese blood donors, we screened 24 292 individuals for the presence of St(a+) with trypsin‐resistant ‘N’ antigen and 193 009 individuals for the presence of St(a+) with trypsin‐resistant M antigen. The breakpoints responsible for the Sta antigen were analysed by sequencing the genomic DNAs. Results A total of 1001 (4·1%) individuals were identified as St(a+) with trypsin‐resistant ‘N’ antigen. Out of 1001 individuals, 115 were selected randomly for sequencing. Two novel GYP*Sch (GYP*401) variants with new intron 3 breakpoints of GYPA were detected in three cases. Twenty‐five (0·013%) individuals were identified as St(a+) with trypsin‐resistant M antigen. Five individuals had the GYP(A‐ψB‐A) hybrid allele; two of these five individuals were GYP*Zan (GYP*101.01), and the remaining three had a novel GYP(A‐ψB‐A) allele with the first breakpoint in GYPA exon A3 between c.178 and c.203. Nine individuals had a novel GYP(A‐E‐A) allele with GYPE exon E2 and pseudoexon E3 instead of GYPA exon A2 and A3. The 11 remaining individuals had a novel GYP(A‐A) allele with a 9‐bp deletion that included the donor splice site of intron 3 of GYPA. Conclusion Our finding on diversity of glycophorin genes responsible for Sta antigen provides evidence for further complexity in the MNS system.
- 21 April 2020
- Published by Wiley in Vox Sanguinis
- Vol. 115 (7) , 579-585
An unusual variant glycophorin expressing protease‐resistant M antigen encoded by the GYPB‐E(2‐4)‐B hybrid gene
Background and objectives: MNS is a highly polymorphic blood group comprising 49 antigens recognized by International Society of Blood Transfusion, some of which may have been generated by genomic recombination among the closely linked genes GYPA, GYPB and GYPE. The GYPE gene has an almost identical sequence to GYPA*01 allele in exon 2 (99% homology), which accounts for M antigen. We investigated an unusual glycophorin molecule with protease‐resistant M antigen.Methods: Blood samples were screened by an automated blood typing system (PK7300) using bromelain‐treated red blood cells (RBCs) and murine monoclonal anti‐M. The M‐positive RBC samples were analysed by immunoblotting using anti‐M as the primary antibody. GYPA, GYPB and GYPE genes were analysed by polymerase chain reaction (PCR), cloning and sequencing using reticulocyte mRNA and genomic DNA.Results: Serological tests and immunoblotting revealed that 103 of the 193 009 individuals (0·0534%) expressed protease‐resistant M‐active glycophorin having a molecular weight of 20 kDa. All the 103 individuals were S+ s− or S− s+. When reticulocyte mRNA from the individuals with M‐active glycophorin (20 kDa) was examined by PCR and cloning followed by sequencing, a novel GYPE‐B hybrid transcript was identified. Long‐range PCR and sequencing using genomic DNA revealed that the individuals had a GYPB‐E(2‐4)‐B hybrid gene. This hybrid gene was predicted to encode a 59‐amino‐acid mature glycoprotein that expresses no S or s antigensConclusions: The prevalence of the M‐active glycophorin (20 kDa) in the Japanese population is 0·0534%. This glycophorin is predicted to be a 59 amino acids polypeptide encoded by the novel GYPB‐E(2‐4)‐B hybrid gene.
- 21 April 2020
- Published by Wiley in Vox Sanguinis
- Vol. 115 (7) , 579-585
An unusual variant glycophorin expressing protease‐resistant M antigen encoded by the GYPB‐E(2‐4)‐B hybrid gene
Background and objectives: MNS is a highly polymorphic blood group comprising 49 antigens recognized by International Society of Blood Transfusion, some of which may have been generated by genomic recombination among the closely linked genes GYPA, GYPB and GYPE. The GYPE gene has an almost identical sequence to GYPA*01 allele in exon 2 (99% homology), which accounts for M antigen. We investigated an unusual glycophorin molecule with protease‐resistant M antigen.Methods: Blood samples were screened by an automated blood typing system (PK7300) using bromelain‐treated red blood cells (RBCs) and murine monoclonal anti‐M. The M‐positive RBC samples were analysed by immunoblotting using anti‐M as the primary antibody. GYPA, GYPB and GYPE genes were analysed by polymerase chain reaction (PCR), cloning and sequencing using reticulocyte mRNA and genomic DNA.Results: Serological tests and immunoblotting revealed that 103 of the 193 009 individuals (0·0534%) expressed protease‐resistant M‐active glycophorin having a molecular weight of 20 kDa. All the 103 individuals were S+ s− or S− s+. When reticulocyte mRNA from the individuals with M‐active glycophorin (20 kDa) was examined by PCR and cloning followed by sequencing, a novel GYPE‐B hybrid transcript was identified. Long‐range PCR and sequencing using genomic DNA revealed that the individuals had a GYPB‐E(2‐4)‐B hybrid gene. This hybrid gene was predicted to encode a 59‐amino‐acid mature glycoprotein that expresses no S or s antigensConclusions: The prevalence of the M‐active glycophorin (20 kDa) in the Japanese population is 0·0534%. This glycophorin is predicted to be a 59 amino acids polypeptide encoded by the novel GYPB‐E(2‐4)‐B hybrid gene.